-
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
Originally Published on Benzinga Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life. The global regenerative medicine market is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019. …
You May Also Like
This Tool Uses IoT to Turn Old Buildings into Data Powerhouses, Improves Air Quality and Keeps Staff Healthy
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
MedTech Company BioSig Technologies Deploys Disruptive Technology To Improve Arrhythmia Care
-
Is It Time To Have A Talk About Poor Ventilation Post COVID-19?
This article was previously published on Benzinga. The average person takes more than 20,000 breaths per day. In fact, by the time they’re 50 years of age, they may have taken somewhere around 400 million breaths in their lifetime. Breathing is essential, and indoor air quality (IAQ) really does matter. Reportedly, the average commercial office building produces more than 39% of the world’s carbon emissions. That energy consumption may impair more than just the climate. Society spends most of its time indoors. And for the modern world, much of this time may be spent living with poor IAQ. IAQ — A Serious Concern? “Good IAQ is directly linked to higher productivity…
-
Biotricity Continues to Transform the Way We Do Health: Medtech Launches New Biokit Solution, Aims at Personal Health Monitoring
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Biotricity (NASDAQ: BTCY) is reforming the healthcare market as one of the fastest-growing companies in medtech. The company bridges the gap in remote cardiac monitoring, preventive and chronic care management by using the power of IoT (internet of things), wearables, and connected devices. Not only does the company offer real-time, comprehensive monitoring and diagnostic services for cardiac-related healthcare and comorbidities, but its devices are also built with features that can dispatch emergency care services should any anomalies or arrhythmias occur when a device is worn. …
-
Research Shows that Animals, too, Need a Good Night’s Sleep
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. There’s a genetic link between narcolepsy, sleeping with one eye open and the so-called “fear conditioning” of so many different animals on this planet. A lack of sleep is not only dangerous to the health of humans but it also puts the health of these animals at risk, no matter their shape, size or species. Social hierarchy, diet, brain size and body mass are contributing factors to how much sleep particular animals naturally need. Outside factors might even include their immediate environment and a…
You May Also Like
Rowdy Rooster Hemp Unleashed | Official Launch of Generation Hemp’s Animal Bedding Brand for Small Animals
Industrial Hemp: Big Win for Pet Stores, Farmers, and Animals
Generation Hemp Reports Quarterly Financial Statements to SEC, Announces New Processing Contracts and Brand Launches
-
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) — recently uplisted to the Nasdaq in lieu of earlier acquisitions involving Cleveland BioLabs and ImQuest Life Sciences, Inc. Last week, the company provided an update on its integration of ImQuest and its plans going forward. According to Statera, preclinical testing is underway in the screening of second-generation immune therapies using the ImQuest platform for the rapid and accurate assessment of various diseases and how the overall makeup and composition of these diseases interact. The company will look more closely…
